AICAR Safety and Side Effects: What Studies Report

Answer first: what the verified literature does and does not contain

AICAR (5-aminoimidazole-4-carboxamide-1-β-D-ribofuranoside) appears in the published record primarily as a laboratory activator of AMP-activated protein kinase (AMPK). In the papers summarised on this page, AICAR and other AMPK-directed tools were applied to cultured cells, rodents and invertebrate models. Researchers described signalling changes, proliferation, mitochondrial behaviour and tissue outcomes. They did not publish human adverse-event frequency tables, tolerability scores or dose-limiting toxicity findings within this set of papers.

That is an absence, and it is stated here as an absence rather than filled in by inference. Because no controlled human safety study appears among the verified papers, this page does not list human side effects, does not rank them by frequency, and does not reproduce any dose figure. Where a claim is made below, the paper reporting it is linked in the same sentence.

This page is for educational purposes only and is not medical advice; consult a licensed physician for any question about health, medication or research participation.

Direct AICAR findings with safety relevance: What Studies Report

Antiproliferative activity and DNA damage in cancer cell models

The most directly relevant paper in this set reported that AICAR suppressed cell proliferation and acted synergistically with decitabine in myelodysplastic syndrome models through the induction of DNA damage (PMID 33788127). Researchers framed this as a potential therapeutic mechanism in a malignant setting, but a compound that reduces proliferation by damaging DNA is, by definition, exerting a stress response on cells rather than a purely metabolic one. The study reported this effect in a laboratory model; it did not report human tolerability, organ-level toxicity or any outcome in healthy tissue.

For anyone reading with a safety question in mind, this is the single most instructive datapoint in the verified set: the reported mechanism of benefit in one disease model is genotoxic stress, and the same paper did not characterise what that mechanism does in non-target tissue.

AMPK pathway context: why activation is not automatically benign

Several verified papers did not test AICAR itself. They map the AMPK pathway that AICAR engages, and they matter here because they show that the direction of an AMPK effect depended on tissue, isoform, timing and the underlying stressor. None of the findings below should be read as an AICAR effect; they are pathway context.

Brain and ischemia: protective in one design, injurious in another

One study reported that small extracellular vesicle–mediated targeting of AMPKα2 produced a neuroprotective effect in cerebral ischemia, an isoform-specific and delivery-specific result (PMID 39961478). A separate paper took the opposite direction, reporting that S-nitrosoglutathione blocked what the researchers called a vicious cycle of nNOS, peroxynitrite and AMPK, with implications for stroke therapy (PMID 26174015). In that framing, AMPK activity formed part of an injurious loop rather than a protective one.

Read together, these two papers illustrate the central interpretive problem in AICAR safety discussion: the same kinase can be described as a target to activate or a target to interrupt, depending on the model and the isoform involved.

Heart and rhythm

Researchers reported that succinate predisposed mice to atrial fibrillation by impairing mitochondrial function via a SUCNR1/AMPK axis, placing AMPK signalling inside an arrhythmia mechanism (PMID 40031129). In a different cardiac context, one study examined mechanisms by which aerobic exercise influenced doxorubicin-induced cardiomyocyte apoptosis through AMPK/PI3K/AKT signalling (PMID 40404115). A third paper reported sex-specific phenotypes in the aging mouse heart with consequences for chronic fibrosis, a reminder that baseline cardiac biology differed by sex and age before any intervention was applied (PMID 35714177).

None of these three papers administered AICAR, and none reported cardiac adverse events attributable to it. They show that cardiac readouts in AMPK research were sensitive to the model's sex, age and co-exposure, which is why extrapolating a cardiac safety profile from pathway papers is not defensible.

Reproductive tissue and gonadal cells

One study reported that AMPK regulated immature boar Sertoli cell proliferation by affecting the CDK4/Cyclin D3 pathway and mitochondrial function (PMID 38714024). In ovarian tissue, researchers reported that RAB5A regulated cell proliferation and lipid metabolism by modulating mitochondrial reactive oxygen species through AMPK signalling in granulosa cells (PMID 42066513). Both papers place AMPK upstream of proliferation control in reproductive cell types, which is a mechanistic observation rather than a reported toxicity.

Glucose handling and metabolic readouts

Metabolic endpoints are where AICAR is most often discussed, but the verified set contains pathway work rather than AICAR safety data. One study reported that acute exercise improved insulin clearance and increased expression of insulin-degrading enzyme in the liver and skeletal muscle of Swiss mice (PMID 27467214). That paper describes an exercise stimulus, not a compound, and reported no adverse metabolic outcome.

Unexpected tissue-specific responses

A dermatology paper reported that biguanides induced acute de novo lipogenesis in human primary sebocytes (PMID 32158247). Biguanides are frequently discussed alongside AMPK biology, and the researchers reported a lipogenic response in a tissue where a lipid-lowering effect might have been assumed. The relevance to an AICAR safety page is narrow but real: metabolic agents did not produce uniform effects across tissues, and skin behaved differently from liver or muscle in that report.

Species and stressor dependence

Two further papers show how far AMPK research ranges beyond mammals. Researchers reported that dichloroacetate and thiamine improved survival and mitochondrial stress in a C. elegans model of dihydrolipoamide dehydrogenase deficiency (PMID 36278487), and a separate study reported the involvement of AMPK α in regulating glycolysis in Yesso scallop under high temperature stress (PMID 37586601). Invertebrate and marine models are useful for mechanism and useless for predicting human tolerability.

Summary table of the verified evidence

Dose, route and duration: what is absent

No dose figure is presented anywhere on this page. The verified papers that involved AICAR did so in cell culture, and the surrounding AMPK literature used genetic tools, other compounds or exercise rather than human administration. Because no verified paper reported a human dose, route, schedule or duration for AICAR, none is repeated, paraphrased or converted here. Readers encountering dose numbers elsewhere should check whether the source is a human trial or an in vitro concentration, since the two are not interchangeable.

What an adverse-event profile would require

A usable human side-effect profile generally rests on a chain of evidence that this set does not contain:

• Single-ascending and multiple-ascending dose studies establishing tolerability limits in people.
• Pharmacokinetic data describing exposure, clearance and accumulation.
• Controlled trials with prespecified safety endpoints and blinded adverse-event adjudication.
• Post-marketing or registry surveillance capturing rare events.
• Long-term follow-up relevant to a pathway that intersects with proliferation and DNA damage, as reported in the myelodysplastic syndrome work (PMID 33788127).

None of those layers appears in the verified papers. The honest description of AICAR's human safety profile, based on this evidence, is that it has not been characterised in the literature reviewed here.

Regulatory status as a factual matter

AICAR is not marketed as an approved human medicine in the United States. Material sold as AICAR is generally labelled research-use-only, which means it is not manufactured, tested or released against the standards applied to human pharmaceuticals, and research-use-only labelling carries no implication of human safety. AICAR is also treated as a prohibited metabolic modulator under international anti-doping rules, a regulatory classification independent of any safety finding. Nothing on this page is legal advice.

How this page relates to the AICAR course

PeptideU's AICAR learning course covers what AMPK is, how AICAR is used as a pathway tool and how to read the study designs involved. This page stays deliberately narrow: it reports what the verified literature says about safety-relevant outcomes and states plainly where human data are missing. The course teaches mechanism; this page handles the adverse-event question.

Limits of this summary

Only the papers listed in the references were used. Most of them studied AMPK biology rather than AICAR administration, and several used non-mammalian models, including an invertebrate mitochondrial disease model (PMID 36278487) and a marine bivalve heat-stress model (PMID 37586601). Findings in cells, mice, nematodes and scallops do not transfer to human risk estimates. Where this page says something was reported, the sentence links the paper that reported it; where it says something is absent, the absence applies to this verified set and not to the entirety of science.

References

• AICAR suppresses cell proliferation and synergizes with decitabine in myelodysplastic syndrome via DNA damage induction (Biotechnology Letters, 2021)
• Neuroprotective effect of small extracellular vesicle-mediated targeting of AMPKα2 in cerebral ischemia (Metabolism: Clinical and Experimental, 2025)
• Blocking a vicious cycle nNOS/peroxynitrite/AMPK by S-nitrosoglutathione: implication for stroke therapy (BMC Neuroscience, 2015)
• Succinate predisposes mice to atrial fibrillation by impairing mitochondrial function via SUCNR1/AMPK axis (Redox Biology, 2025)
• Mechanisms of aerobic exercise on doxorubicin-induced cardiomyocyte apoptosis: based on AMPK/PI3K/AKT signalling pathway (Life Sciences, 2025)
• Sex-specific phenotypes in the aging mouse heart and consequences for chronic fibrosis (American Journal of Physiology. Heart and Circulatory Physiology, 2022)
• AMPK regulates immature boar Sertoli cell proliferation through affecting CDK4/Cyclin D3 pathway and mitochondrial function (Theriogenology, 2024)
• RAB5A regulates cell proliferation and lipid metabolism by modulating mitochondrial ROS via AMPK signaling pathway in ovarian granulosa cells (Redox Biology, 2026)
• Acute Exercise Improves Insulin Clearance and Increases the Expression of Insulin-Degrading Enzyme in the Liver and Skeletal Muscle of Swiss Mice (PLoS One, 2016)
• Biguanides Induce Acute de novo Lipogenesis in Human Primary Sebocytes (Clinical, Cosmetic and Investigational Dermatology, 2020)
• Dichloroacetate and thiamine improve survival and mitochondrial stress in a C. elegans model of dihydrolipoamide dehydrogenase deficiency (JCI Insight, 2022)
• The involvement of AMP-activated protein kinase α in regulating glycolysis in Yesso scallop Patinopecten yessoensis under high temperature stress (Fish & Shellfish Immunology, 2023)